Cross-Population Transfer Learning for Antidepressant Treatment Response Prediction: A SHAP-Based Explainability Approach Using Synthetic Multi-Ethnic Data
Accurate prediction of antidepressant treatment response remains a major challenge in psychiatry, particularly across diverse patient populations where genetic, demographic, and clinical characteristics vary substantially. In this study, we evaluate the potential of transfer learning to enhance predictive performance across heterogeneous cohorts. We generated a synthetic, population-stratified dataset representing four major demographic groups, European, East Asian, African, and Latin American, each characterized by clinical variables (age, gender, BMI, baseline Hamilton Depression Rating Scale [HAMD] score) and genetic factors (SNP1, SNP2, CYP2D6 metabolizer status). A baseline feedforward neural network was trained exclusively on the European cohort and assessed for zero-shot generalization to the remaining populations. Transfer learning was then applied by fine-tuning the base model on small samples from each target cohort. Model performance was quantified using AUROC, accuracy, and bootstrap-derived 95% confidence intervals. Explainability was incorporated via SHAP KernelExplainer to produce global feature importance rankings and local, instance-level explanations. The baseline model achieved high discrimination in European (AUROC 0.746) and African (0.714) cohorts but exhibited markedly reduced performance in East Asian (0.501) and Latin American (0.658) populations. SHAP analysis consistently identified gender, age, and baseline HAMD as top predictors, with CYP2D6 metabolizer status and SNP1 allele frequency contributing variably across populations. These results underscore the importance of population-specific fine-tuning to mitigate performance degradation when applying models beyond their source domain. Furthermore, the integration of SHAP explanations facilitates model interpretability, enabling clinicians to assess feature-level contributions and identify potential biases. While demonstrated here on synthetic data, this methodological framework provides a robust foundation for future validation using real-world, multi-ethnic patient datasets.
Cite this paper
Filippis, R. D. and Foysal, A. A. (2026). Cross-Population Transfer Learning for Antidepressant Treatment Response Prediction: A SHAP-Based Explainability Approach Using Synthetic Multi-Ethnic Data. Open Access Library Journal, 13, e14445. doi: http://dx.doi.org/10.4236/oalib.1114445.
Shalimova, A., Babasieva, V., Chubarev, V.N., Tarasov, V.V., Schiöth, H.B. and Mwinyi, J. (2021) Therapy Response Prediction in Major Depressive Disorder: Current and Novel Genomic Markers Influencing Pharmacokinetics and Phar-macodynamics. Pharmacogenomics, 22, 485-503.
Lloret-Linares, C., Bellivier, F., Haffen, E., Aubry, J., Daali, Y., Heron, K., et al. (2015) Markers of Individual Drug Metabolism: Towards the Development of a Personalized Anti-depressant Prescription. Current Drug Metabolism, 16, 17-45. https://doi.org/10.2174/138920021601150702160728
Levy, A., El-Hage, W., Bennabi, D., Allauze, E., Bouvard, A., Camus, V., et al. (2021) Oc-currence of Side Effects in Treatment-Resistant Depression: Role of Clinical, So-cio-Demographic and Environmental Characteristics. Frontiers in Psychiatry, 12, Article 795666. https://doi.org/10.3389/fpsyt.2021.795666
Zheng, N., Niu, M.X., Zang, Y.N., Zhuang, H.Y., et al. (2023) Which Can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic Genes? Current Drug Metabolism, 24, 525-535. https://doi.org/10.2174/1389200224666230907093349
Eap, C.B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., et al. (2021) Tools for Optimising Pharmacotherapy in Psychiatry (Therapeutic Drug Moni-toring, Molecular Brain Imaging and Pharmacogenetic Tests): Focus on Antide-pressants. The World Journal of Biological Psychiatry, 22, 561-628. https://doi.org/10.1080/15622975.2021.1878427
Li, D.Y., Lin, Y.H., Davies, H.L., Zvrskovec, J.K., et al. (2024) Prediction of Antidepressant Side Ef-fects in the Genetic Link to Anxiety and Depression Study.
Keers, R. and Aitchison, K.J. (2010) Gender Differences in Antidepressant Drug Response. International Review of Psychiatry, 22, 485-500. https://doi.org/10.3109/09540261.2010.496448
Langmia, I.M., Just, K.S., Yamoune, S., Brockmöller, J., Masimirembwa, C. and Stingl, J.C. (2021) CYP2B6 Functional Variability in Drug Metabolism and Exposure across Popula-tions—Implication for Drug Safety, Dosing, and Individualized Therapy. Fron-tiers in Genetics, 12, Article 692234. https://doi.org/10.3389/fgene.2021.692234
Lai, Y.R., Varma, M., Feng, B., Stephens, J.C., Kimoto, E., El-Kattan, A., et al. (2012) Impact of Drug Trans-porter Pharmacogenomics on Pharmacokinetic and Pharmacodynamic Variabil-ity—Considerations for Drug Development. Expert Opinion on Drug Metabolism & Toxicology, 8, 723-743. https://doi.org/10.1517/17425255.2012.678048
Gervasini, G., Benítez, J. and Carrillo, J.A. (2010) Pharmacogenetic Testing and Therapeutic Drug Monitoring Are Complementary Tools for Optimal Individualization of Drug Therapy. European Journal of Clinical Pharmacology, 66, 755-774. https://doi.org/10.1007/s00228-010-0857-7.
Arango, C., Kapur, S. and Kahn, R.S. (2015) Going beyond “trial-and-Error” in Psychiatric Treatments: Opti-mise-Ing the Treatment of First Episode of Schizophrenia. Schizophrenia Bulle-tin, 41, 546-548. https://doi.org/10.1093/schbul/sbv026
Huang, M. and Pan, H.Y. (2023) Pharmacogenomic Profiling to Tailor Antidepressant Therapy: Improving Treatment Outcomes and Reducing Adverse Drug Reac-tions in Major Depressive Disorder. SHIFAA, 2023, 19-31. https://doi.org/10.70470/shifaa/2023/003
Holmes, E.A., Ghaderi, A., Harmer, C.J., Ramchandani, P.G., Cuijpers, P., Morrison, A.P., et al. (2018) The Lancet Psychiatry Commission on Psychological Treatments Research in Tomor-row’s Science. The Lancet Psychiatry, 5, 237-286. https://doi.org/10.1016/s2215-0366(17)30513-8
Niu, S.T., Liu, Y.X., Wang, J. and Song, H.B. (2021) A Decade Survey of Transfer Learning (2010-2020). IEEE Transactions on Artificial Intelligence, 1, 151-166. https://doi.org/10.1109/tai.2021.3054609
Hosna, A., Merry, E., Gyalmo, J., Alom, Z., Aung, Z. and Azim, M.A. (2022) Transfer Learning: A Friendly In-troduction. Journal of Big Data, 9, Article No. 102. https://doi.org/10.1186/s40537-022-00652-w
Yan, P., Abdulkadir, A., Luley, P., Rosenthal, M., Schatte, G.A., Grewe, B.F., et al. (2024) A Comprehen-sive Survey of Deep Transfer Learning for Anomaly Detection in Industrial Time Series: Methods, Applications, and Directions. IEEE Access, 12, 3768-3789. https://doi.org/10.1109/access.2023.3349132
Zhu, Z.D., Lin, K.X., Jain, A.K. and Zhou, J.Y. (2023) Transfer Learning in Deep Reinforcement Learning: A Survey. IEEE Transactions on Pattern Analysis and Machine Intelligence, 45, 13344-13362. https://doi.org/10.1109/tpami.2023.3292075
Costa-Jussà, M.R., Cross, J., Çelebi, O., Elbayad, M., et al. (2022) No Language Left behind: Scaling Hu-man-Centered Machine Translation. arXiv: 2207.04672.
Patil, R. and Gudivada, V. (2024) A Review of Current Trends, Techniques, and Challenges in Large Language Models (LLMs). Applied Sciences, 14, Article 2074. https://doi.org/10.3390/app14052074
Hammad, M. and Ahmad, S. (2025) Machine Learning for Image Processing in Healthcare. In: Advances in Computational Intelligence and Robotics, IGI Global, 131-182. https://doi.org/10.4018/979-8-3373-0548-6.ch005
Wang, Y.F. (2024) A Comparative Analysis of Model Agnostic Techniques for Explainable Artificial Intelligence. Research Reports on Computer Science, 3, 25-33. https://doi.org/10.37256/rrcs.3220244750
Parisineni, S.R.A. and Pal, M. (2024) Enhancing Trust and Interpretability of Complex Machine Learning Models Using Local Interpretable Model Agnostic Shap Explanations. Interna-tional Journal of Data Science and Analytics, 18, 457-466. https://doi.org/10.1007/s41060-023-00458-w
Qadri, Y.A., Shaikh, S., Ahmad, K., Choi, I., Kim, S.W. and Vasilakos, A.V. (2025) Explainable Artificial Intelligence: A Perspective on Drug Discovery. Pharmaceutics, 17, Article 1119. https://doi.org/10.3390/pharmaceutics17091119
Sadeghi, Z., Alizadehsani, R., Cifci, M.A., Kausar, S., et al. (2023) A Brief Review of Explain-able Artificial Intelligence in Healthcare. arXiv: 2304.01543.
Kelly, B.S., Mathur, P., Plesniar, J., Lawlor, A. and Killeen, R.P. (2023) Using Deep Learn-ing-Derived Image Features in Radiologic Time Series to Make Personalised Predictions: Proof of Concept in Colonic Transit Data. European Radiology, 33, 8376-8386. https://doi.org/10.1007/s00330-023-09769-9
Cysouw, M.C.F., Jansen, B.H.E., van de Brug, T., Oprea-Lager, D.E., Pfaehler, E., de Vries, B.M., et al. (2020) Machine Learning-Based Analysis of [18F]DCFPyL PET Radi-omics for Risk Stratification in Primary Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48, 340-349. https://doi.org/10.1007/s00259-020-04971-z
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T. and Leeder, J.S. (2017) Prediction of CYP2D6 Phenotype from Genotype across World Populations. Genetics in Medicine, 19, 69-76. https://doi.org/10.1038/gim.2016.80
Laing, E., Hess, R.P., Shen, Y.J., Wang, J. and Hu, S.X. (2011) The Role and Impact of SNPs in Phar-macogenomics and Personalized Medicine. Current Drug Metabolism, 12, 460-486. https://doi.org/10.2174/138920011795495268
Luczak, T., Stenehjem, D. and Brown, J. (2021) Applying an Equity Lens to Pharmaco-genetic Research and Translation to Under-Represented Populations. Clinical and Translational Science, 14, 2117-2123. https://doi.org/10.1111/cts.13110
Bousquet, J., Anto, J.M., Annesi-Maesano, I., Dedeu, T., Dupas, E., Pépin, J., et al. (2018) POLLAR: Impact of Air Pollution on Asthma and Rhinitis; A European Institute of Innovation and Technology Health (EIT Health) Project. Clinical and Transla-tional Allergy, 8, Article No. 36. https://doi.org/10.1186/s13601-018-0221-z
Ponce-Bobadilla, A.V., Schmitt, V., Maier, C.S., Mensing, S. and Stodtmann, S. (2024) Practical Guide to Shap Analysis: Explaining Supervised Machine Learning Model Predictions in Drug Development. Clinical and Translational Science, 17, e70056. https://doi.org/10.1111/cts.70056
Pelosi, D., Cacciagrano, D. and Pian-gerelli, M. (2025) Explainability and Interpretability in Concept and Data Drift: A Systematic Literature Review. Algorithms, 18, Article 443. https://doi.org/10.3390/a18070443
Ferrari, D., Guidetti, V., Wang, Y. and Curcin, V. (2023) Multi-objective Symbolic Regression to Generate Da-ta-Driven, Non-Fixed Structure and Intelligible Mortality Predictors Using Ehr: Binary Classification Methodology and Comparison with State-of-the-Art. AMIA Annual Symposium Proceedings, 2022, 442-451.
Kouw, W.M. and Loog, M. (2019) A Review of Domain Adaptation without Target Labels. IEEE Trans-actions on Pattern Analysis and Machine Intelligence, 43, 766-785. https://doi.org/10.1109/tpami.2019.2945942
Wilson, G. and Cook, D.J. (2020) A Survey of Unsupervised Deep Domain Adaptation. ACM Transactions on Intelligent Systems and Technology, 11, 1-46. https://doi.org/10.1145/3400066
Sarafian, R., Kloog, I., Sarafian, E., Hough, I. and Rosenblatt, J.D. (2020) A Domain Adaptation Approach for Per-formance Estimation of Spatial Predictions. IEEE Transactions on Geoscience and Remote Sensing, 59, 5197-5205. https://doi.org/10.1109/tgrs.2020.3012575
Bolte, J.A., Kamp, M., Breuer, A., Homoceanu, S., Schlicht, P., Huger, F., et al. (2019) Unsupervised Domain Ad-aptation to Improve Image Segmentation Quality Both in the Source and Target Domain. 2019 IEEE/CVF Conference on Computer Vision and Pattern Recogni-tion Workshops (CVPRW), Long Beach, 16-17 June 2019, 1404-1413. https://doi.org/10.1109/cvprw.2019.00181
Oza, P., Sindagi, V.A., VS, V. and Patel, V.M. (2024) Unsupervised Domain Adaptation of Object Detectors: A Survey. IEEE Transactions on Pattern Analysis and Machine Intelligence, 46, 4018-4040. https://doi.org/10.1109/tpami.2022.3217046
Akhtar, M.A.K., Kumar, M. and Nayyar, A. (2024) Transparency and Accountability in Explainable AI: Best Practices. In: Studies in Systems, Decision and Control, Springer, 127-164. https://doi.org/10.1007/978-3-031-66489-2_5
Akhtar, M.A.K., Mohit, K. and Anand, N. (2024) Socially Responsible Applications of Explainable AI. In: Towards Ethical and Socially Responsible Explainable AI: Challenges and Op-portunities, Springer, 261-350.
Oluwagbade, E., Alemede, V., Odumbo, O. and Blessing, A. (2023) Lifecycle Governance for Explainable AI in Pharmaceu-tical Supply Chains: A Framework for Continuous Validation, Bias Auditing, and Equitable Healthcare Delivery. International Journal of Engineering Technology Research & Management, 7, Article 54.
Moreno-Sánchez, P.A., Del Ser, J., van Gils, M. and Hernesniemi, J. (2025) A Design Framework for Operationaliz-ing Trustworthy Artificial Intelligence in Healthcare: Requirements, Tradeoffs and Challenges for Its Clinical Adoption. arXiv: 2504.19179.
Vetrivel, S., Saravanan, T., Maheswari, R. and Arun, V. (2025) Ethical Considerations Pri-vacy, Fairness, Bias in Genomic Data. In: Applications of Deep Learning in Ge-nomics, CRC Press, 220-255. https://doi.org/10.1201/9781003558835-12
Gupta, R., Sasaki, M., Taylor, S.L., Fan, S., Hoch, J.S., Zhang, Y., et al. (2025) Developing and Applying the BE-FAIR Equity Framework to a Population Health Predictive Model: A Ret-rospective Observational Cohort Study. Journal of General Internal Medicine, 40, 2537-2547. https://doi.org/10.1007/s11606-025-09462-1
Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., et al. (2024) Advancing Precision Medicine: A Review of Innovative in Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics, 16, Article 332. https://doi.org/10.3390/pharmaceutics16030332
Rahman, E., Webb, W.R., Rao, P. and Carruthers, J.D.A. (2025) Mutation-Aware Formulation: A Genomic Framework for Equitable Global Dermocosmetics. Human Genetics, 144, 1011-1034.
Guha, N., Lawrence, C.M., Gailmard, L.A., Rodolfa, K.T., et al. (2024) AI Regulation Has Its Own Alignment Problem: The Technical and In-stitutional Feasibility of Disclosure, Registration, Licensing, and Auditing. The George Washington Law Review, 92, Article 1473.
Caspers, J. (2021) Translation of Predictive Modeling and AI into Clinics: A Question of Trust. Eu-ropean Radiology, 31, 4947-4948. https://doi.org/10.1007/s00330-021-07977-9
Ennab, M. and Mcheick, H. (2024) Enhancing Interpretability and Accuracy of AI Models in Healthcare: A Comprehensive Review on Challenges and Future Directions. Frontiers in Ro-botics and AI, 11, Article 1444763. https://doi.org/10.3389/frobt.2024.1444763
Goktas, P. and Grzyb-owski, A. (2025) Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI. Journal of Clinical Medicine, 14, Article 1605. https://doi.org/10.3390/jcm14051605
Lenhof, K., Eckhart, L., Rolli, L. and Lenhof, H. (2024) Trust Me If You Can: A Survey on Reliability and Inter-pretability of Machine Learning Approaches for Drug Sensitivity Prediction in Cancer. Briefings in Bioinformatics, 25, bbae379. https://doi.org/10.1093/bib/bbae379
Sankar, B.S., Gilliland, D., Rincon, J., Hermjakob, H., Yan, Y., Adam, I., et al. (2024) Building an Ethical and Trustworthy Biomedical AI Ecosystem for the Translational and Clinical Integra-tion of Foundation Models. Bioengineering, 11, Article 984. https://doi.org/10.3390/bioengineering11100984